Glaukos Co. (NYSE:GKOS) Shares Bought by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P grew its position in Glaukos Co. (NYSE:GKOS) by 21.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 673,751 shares of the medical instruments supplier’s stock after buying an additional 119,527 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Glaukos were worth $87,776,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Values First Advisors Inc. purchased a new position in Glaukos in the third quarter valued at $25,000. Harvest Fund Management Co. Ltd raised its position in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 860 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Glaukos by 68.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,192 shares of the medical instruments supplier’s stock valued at $141,000 after buying an additional 486 shares during the period. KBC Group NV grew its position in shares of Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC acquired a new position in shares of Glaukos during the second quarter worth about $187,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total value of $316,156.75. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $14,198,425.93. The trade was a 2.18 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. The trade was a 8.49 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

GKOS has been the subject of a number of recent research reports. Truist Financial lifted their price target on shares of Glaukos from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Wells Fargo & Company lifted their price objective on shares of Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Needham & Company LLC increased their target price on Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. StockNews.com raised Glaukos from a “sell” rating to a “hold” rating in a report on Monday, October 21st. Finally, Stifel Nicolaus increased their price objective on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $134.55.

Glaukos Trading Up 2.3 %

GKOS opened at $144.00 on Monday. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $146.09. The business’s 50 day moving average is $132.40 and its two-hundred day moving average is $123.80.

Glaukos (NYSE:GKOS) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The company’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period in the previous year, the company posted ($0.50) EPS. Analysts predict that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.